AZN vs EXEL
AstraZeneca PLC vs Exelixis — AI-powered side-by-side comparison
AZN
AstraZeneca PLC
56
Watch
VS
| Metric | AZN | EXEL |
|---|
| AI Score |
56
|
67
|
| Price |
$158.74
|
$51.30
|
| P/E Ratio |
23.81×
|
15.60×
|
| ROE |
21.1%
|
36.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
79.3%
|
96.5%
|
| Debt / Equity |
0.64×
|
0.09×
|
| Dividend Yield |
1.3%
|
0.0%
|
| RSI (14) |
33.8
|
41.0
|
| Beta |
0.211
|
0.422
|
| Expected Upside |
—
|
+8.7%
|
AI Committee View
Current Innellis committee reasoning for AZN versus EXEL.
EXEL leads by 11 points.
EXEL scores 67/100 (Buy) versus AZN at 56/100 (Watch).
AZN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — current ratio of 0.94 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- ROE of 21.7% shows genuine earnings power backing the valuation — Value
- EPS growing 25.9% YoY — Growth
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price-to-book of 5.9x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical
- MACD histogram negative -- bearish momentum — Technical
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical